Tanomastat

• UNSPSC Description:

  Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The Ki values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models[1][2][3].

• Target Antigen:

  MMP

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tanomastat.html

• Purity:

  99.5

• Solubility:

  DMSO : 25 mg/mL (ultrasonic;warming)

• Smiles:

  ClC1=CC=C(C2=CC=C(C(C[C@H](CSC3=CC=CC=C3)C(O)=O)=O)C=C2)C=C1

• Molecular Weight:

  410.91

• References & Citations:

  [1]Leung D, et al. Protease inhibitors: current status and future prospects. J Med Chem. 2000 Feb 10;43(3):305-41.|[2]Gatto C, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res. 1999 Nov;5(11):3603-7.|[3]Nozaki S, et al. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancerorthotopic model. Clin Exp Metastasis. 2003;20(5):407-12.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  Phase 3

• CAS Number:

  179545-77-8